Olmesartan Expiry In Mind As Daiichi Sankyo Shakes Up

Major Japanese firm Daiichi Sankyo has unveiled a fundamental shakeup across its corporate structure that will see a cut in the number of divisions and simplification of reporting lines, as it battens down and cuts costs ahead of olmesartan's loss of exclusivity.